The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS
ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
EFFECT OF EMPAGLIFLOZIN ON LIVER FAT IN METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITHOUT DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
PROJECTED PREVALENCE OF CIRRHOSIS AND OVERT HEPATIC ENCEPHALOPATHY IN THE UNITED STATES, 2021–2030
EVALUATING THE IMPACT OF CO-EXISTING INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A LARGE COHORT RETROSPECTIVE STUDY
SOCIETY: AASLD Join AASLD for an enlightening session where experts delve into groundbreaking research at the intersection of microbiome science and liver health…